Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Accounts Payables (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Accounts Payables for 9 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 27.78% to $7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, down 27.78% year-over-year, with the annual reading at $7.6 million for FY2025, 27.78% down from the prior year.
  • Accounts Payables hit $7.6 million in Q4 2025 for Sutro Biopharma, up from $7.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $12.6 million in Q2 2022 to a low of $3.9 million in Q2 2023.
  • Historically, Accounts Payables has averaged $7.6 million across 5 years, with a median of $7.3 million in 2024.
  • Biggest five-year swings in Accounts Payables: soared 129.0% in 2021 and later tumbled 69.32% in 2023.
  • Year by year, Accounts Payables stood at $6.0 million in 2021, then fell by 20.17% to $4.8 million in 2022, then soared by 96.79% to $9.4 million in 2023, then grew by 10.96% to $10.5 million in 2024, then decreased by 27.78% to $7.6 million in 2025.
  • Business Quant data shows Accounts Payables for STRO at $7.6 million in Q4 2025, $7.0 million in Q3 2025, and $4.3 million in Q2 2025.